Capricor Therapeutics (CAPR) Total Liabilities (2010 - 2026)

Capricor Therapeutics' Total Liabilities history runs 17 years deep, the most recent figure standing at $47.6 million for Q1 2026.

• In Q1 2026, Total Liabilities rose 82.16% year-over-year to $47.6 million; the TTM figure through Mar 2026 stood at $47.6 million (up 82.16% YoY), while the FY2025 annual figure was $50.2 million, up 100.48% from the prior year.
• Total Liabilities was $47.6 million for Q1 2026 at Capricor Therapeutics, down from $50.2 million in the prior quarter.
• In the past five years, Total Liabilities ranged from a high of $50.2 million in Q4 2025 to a low of $24.7 million in Q3 2024.
• Historically, Total Liabilities has averaged $36.8 million across 5 years, with a median of $38.5 million in 2022.
• The sharpest annual moves came in 2022 and 2024: Total Liabilities soared 504.94% in 2022, then plunged 38.14% in 2024.
• A 5-year view of Total Liabilities shows it stood at $38.3 million in 2022, then retreated by 5.68% to $36.1 million in 2023, then plunged by 30.76% to $25.0 million in 2024, then soared by 100.48% to $50.2 million in 2025, then dropped by 5.14% to $47.6 million in 2026.
• The last three Total Liabilities figures came in at $47.6 million (Q1 2026), $50.2 million (Q4 2025), and $42.6 million (Q3 2025), per Business Quant data.